Jan. 16 at 6:12 PM
$SLS $ABBV $PFE OpEx manipulation giving everyone, one last day of Discounted Pricing - Share Price ReRATING Begins Tuesday.
- a Nice LONG WEEKEND while the market digests the Fact Gps Phase 3 Registrational Results are coming
- THE FUTURE is Inevitable
Gps will treat 40,000 to 50,000 AML Remission Patients Each year - and there are 100,000 right now Currently. in Remission who'll benefit from and be Eligible for GPS Immunotherapy.
SLS published estimated pricing comps starting at
$280K Rev Per Patient in Year 1.
$28B Total Addressable Market - upon Approval... this $.67B Manipulated equity is worth
$40B to Big Pharma.
Everyone at
$IBRX Knows --- Short TIME is UP
